RSS
Логотип
Баннер в шапке 1
Баннер в шапке 2

Apollo MRI (pacemaker)

Product
Developers: Cardioelectronics
Date of the premiere of the system: October 2025
Branches: Pharmaceuticals, Medicine, Healthcare

Content

History

2025: Product Announcement

Rostec State Corporation has launched mass production of the first domestic electrocardiostimulator compatible with magnetic resonance imaging. The Apollo MRI device is designed for patients with severe arrhythmias. The main advantage of the device is the ability to undergo MRI examinations without restrictions, which is not available when using conventional models. The start of the issue was reported by the Rostec press service on October 6, 2025.

The Apollo MRI electrocardiostimulator is manufactured by Cardioelectronics, which is part of the state corporation. The device implants under the skin and constantly monitors the frequency and regularity of heart rhythm. This takes into account the individual physiological characteristics of the patient.

Apollo MRI

The device is able to accumulate data on the work of the heart. This allows the doctor to obtain an objective picture of the patient's condition and adjust the treatment based on the information collected. Continuous monitoring of cardiac activity makes it possible to detect rhythm disorders in a timely manner.

The key difference between Apollo MRI and traditional pacemakers is compatibility with magnetic resonance imaging. Patients with conventional implant models cannot undergo MRI diagnosis due to the risk of damage to the device or exposure to the body. The new development opens up access to modern diagnostic methods and improves the effectiveness of treatment.

General Director of RT-MedTech Sergei Dmitrochenko called the launch of serial production an important step in the development of domestic medical instrumentation. He stressed that the priority task of Rostec is the development and production of modern medical devices, especially those that are vital for patients. By 2027, the company plans to increase production and reach volumes of up to 5,000 devices per year. This will provide Russian patients with modern and safe technologies, as well as reduce the country's dependence on imports in cardiology.[1]

Notes